Governance & Derivative

ImmunityBio, Inc. (NasdaqGS: IBRX)

Contact a Lawyer Now

(833) 938-0905

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (“ImmunityBio”) (NasdaqGS: IBRX).

In December 2024 , ImmunityBio amended the $505 million note that it owed to affiliates of Dr. Patrick Soon-Shiong, ImmunityBio’s Executive Chairman and controlling stockholder. In January 2026, ImmunityBio amended the note again in a manner that appears to favor the interests of Soon-Shiong. KSF is investigating the fairness of the note amendments, including whether ImmunityBio’s officers, directors or controlling stockholder breached their fiduciary duties in connection with the amendments.

If you have information that would assist KSF in its investigation, or have been a long-term holder of ImmunityBio shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at (833) 938-0905 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or fill out the form on this page.